Hospital
Manatee Memorial Hospital L P
Manatee Memorial Hospital L P was paid $22.33M by Medicaid between Jan 2018 and Dec 2024, across 194 billing codes. Its largest line is 99283, emergency room visit (moderate) — 17% of everything it billed.
33Billing provider infoMANATEE MEMORIAL HOSPITAL L P
BRADENTON, FL 34208
BRADENTON, FL 34208
33aNPI1760472799assigned 10/21/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$22.33M
24GClaims739,091
24DCodes billed194
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#12 of 163
Median peer was paid$4.77M
This provider vs. median4.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FILTON, STEVE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 46,375 | $762K | |
| 2019 | 145,642 | $4.01M | |
| 2020 | 124,300 | $2.65M | |
| 2021 | 142,037 | $3.80M | |
| 2022 | 134,917 | $4.69M | |
| 2023 | 89,488 | $3.82M | |
| 2024incomplete | 56,332 | $2.60M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 45,452 | 41,416 | $3.84M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 44,318 | 38,626 | $3.71M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 33,669 | 23,679 | $2.44M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 7.9% | 13,029 | 2,896 | $1.76M |
| 36415 | Collection of venous blood by venipuncture | 7.4% | 47,632 | 35,987 | $1.66M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 4.3% | 11,995 | 9,091 | $954K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.5% | 11,451 | 9,484 | $791K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.5% | 3,954 | 3,481 | $779K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.2% | 5,488 | 4,467 | $710K |
| G0378 | Hospital observation service, per hour | 3.0% | 3,614 | 2,055 | $677K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 3.0% | 11,406 | 2,594 | $673K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.7% | 7,215 | 6,701 | $600K |
182 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.5% | 1,976 | $338K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.5% | 13,014 | $338K |
| 59025 | Fetal non-stress test | 1.1% | 6,339 | $235K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.0% | 10,774 | $227K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,965 | $198K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 3,995 | $175K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,089 | $122K |
| 71045 | Radiologic examination, chest; single view | <1% | 16,328 | $117K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 541 | $90K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 7,228 | $76K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,450 | $71K |
| 80053 | Comprehensive metabolic panel | <1% | 21,844 | $70K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,228 | $68K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 7,323 | $65K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 15,234 | $61K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 14,871 | $56K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,814 | $55K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 20,278 | $53K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,130 | $53K |
| 92526 | <1% | 4,712 | $52K | |
| 12001 | <1% | 773 | $45K | |
| A9270 | Non-covered item or service | <1% | 8,727 | $40K |
| 12011 | <1% | 518 | $38K | |
| 73610 | <1% | 1,278 | $37K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 3,211 | $35K |
| 73130 | <1% | 1,269 | $34K | |
| 87070 | <1% | 1,343 | $33K | |
| 73630 | <1% | 1,580 | $33K | |
| 81001 | <1% | 25,227 | $33K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,894 | $32K |
| 73564 | <1% | 1,484 | $32K | |
| 81003 | <1% | 7,238 | $31K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 261 | $27K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 623 | $27K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 308 | $26K |
| 82948 | <1% | 3,463 | $26K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 39,383 | $26K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,347 | $24K |
| 87077 | <1% | 3,276 | $23K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,708 | $23K |
| 74018 | <1% | 1,277 | $23K | |
| 81025 | <1% | 12,625 | $22K | |
| 73110 | <1% | 714 | $22K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,856 | $21K |
| 76801 | <1% | 2,335 | $20K | |
| 87420 | <1% | 686 | $20K | |
| 97161 | <1% | 228 | $20K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 756 | $18K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,913 | $17K |
| 86850 | <1% | 2,560 | $16K | |
| 73030 | <1% | 943 | $16K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,424 | $15K |
| 97162 | <1% | 102 | $14K | |
| C1769 | Guide wire | <1% | 240 | $13K |
| 85610 | <1% | 6,989 | $12K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,063 | $12K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,399 | $11K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 7,153 | $11K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 27 | $11K |
| 97116 | <1% | 183 | $11K | |
| 85730 | <1% | 6,040 | $10K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,010 | $10K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,616 | $10K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 914 | $10K |
| 73080 | <1% | 313 | $10K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,592 | $10K |
| 87641 | <1% | 1,355 | $9K | |
| 72100 | <1% | 837 | $8K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,914 | $8K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,301 | $8K |
| 93971 | <1% | 492 | $8K | |
| 82962 | <1% | 2,464 | $8K | |
| 86900 | <1% | 3,882 | $7K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,184 | $7K |
| 87480 | <1% | 816 | $7K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,163 | $7K |
| 73090 | <1% | 144 | $5K | |
| 84702 | <1% | 4,332 | $5K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 18 | $5K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,130 | $5K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,051 | $5K |
| 76830 | Ultrasound, transvaginal | <1% | 159 | $5K |
| 84112 | <1% | 240 | $4K | |
| 70486 | <1% | 105 | $4K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,179 | $4K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 68 | $4K |
| 29125 | <1% | 288 | $4K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 79 | $4K |
| 87186 | <1% | 3,448 | $4K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 185 | $3K |
| 84484 | <1% | 8,194 | $3K | |
| 82731 | <1% | 158 | $3K | |
| 73140 | <1% | 47 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,223 | $3K |
| 12002 | <1% | 58 | $3K | |
| 72131 | <1% | 30 | $3K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 300 | $2K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 68 | $2K |
| 83880 | <1% | 2,139 | $2K | |
| 73502 | <1% | 141 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,839 | $2K |
| 83690 | <1% | 8,373 | $2K | |
| 87205 | <1% | 363 | $2K | |
| 96376 | <1% | 952 | $2K | |
| 87040 | <1% | 1,858 | $2K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 3,762 | $2K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 406 | $2K |
| 85027 | <1% | 2,094 | $2K | |
| 93970 | <1% | 60 | $1K | |
| 87653 | <1% | 1,057 | $1K | |
| 87430 | <1% | 756 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,014 | $1K |
| 83735 | <1% | 4,603 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,588 | $1K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,488 | $1K |
| 86901 | <1% | 3,849 | $1K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 15 | $1K |
| 73590 | <1% | 57 | $1K | |
| 85379 | <1% | 1,258 | $1K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 32 | $1K |
| 92523 | <1% | 34 | $1K | |
| 87510 | <1% | 817 | $925.44 | |
| 82247 | <1% | 301 | $797.94 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,512 | $699.72 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,432 | $599.76 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 912 | $583.93 |
| 83605 | <1% | 1,086 | $559.68 | |
| 10060 | <1% | 14 | $534.35 | |
| 72040 | <1% | 32 | $474.40 | |
| 84439 | <1% | 483 | $441.55 | |
| 71101 | <1% | 16 | $411.89 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,324 | $407.61 |
| 82565 | <1% | 69 | $353.51 | |
| 85384 | <1% | 141 | $302.13 | |
| 87660 | <1% | 830 | $291.99 | |
| 80061 | Lipid panel | <1% | 532 | $282.11 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 496 | $272.15 |
| 82550 | <1% | 747 | $260.30 | |
| 87899 | <1% | 822 | $234.48 | |
| 90714 | <1% | 245 | $227.96 | |
| 29515 | <1% | 35 | $207.52 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,745 | $189.27 |
| 0353U | <1% | 299 | $187.79 | |
| 87561 | <1% | 97 | $187.73 | |
| 86592 | <1% | 248 | $128.33 | |
| 82248 | <1% | 358 | $127.55 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 26 | $120.00 |
| 74019 | <1% | 12 | $114.96 | |
| 72170 | <1% | 17 | $100.87 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 852 | $88.42 |
| 90715 | <1% | 363 | $85.87 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 137 | $82.50 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 400 | $74.70 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,605 | $64.41 |
| 84550 | <1% | 285 | $51.66 | |
| 87340 | <1% | 433 | $48.97 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 180 | $41.53 |
| 88342 | <1% | 15 | $41.08 | |
| 82150 | <1% | 110 | $24.55 | |
| 82728 | <1% | 126 | $22.20 | |
| 84100 | <1% | 350 | $19.07 | |
| 85049 | <1% | 16 | $16.18 | |
| 85651 | <1% | 189 | $14.83 | |
| 85007 | <1% | 30 | $14.77 | |
| 83615 | <1% | 85 | $12.95 | |
| 80076 | <1% | 55 | $6.79 | |
| 86141 | <1% | 98 | $6.61 | |
| 83540 | <1% | 147 | $6.07 | |
| 80050 | General health panel | <1% | 29 | $5.87 |
| 87210 | <1% | 16 | $3.84 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 902 | $0.00 |
| J2800 | Injection, methocarbamol, up to 10 ml | 0% | 29 | $0.00 |
| 82010 | 0% | 17 | $0.00 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 0% | 30 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 14 | $0.00 |
| 84145 | 0% | 30 | $0.00 | |
| Q5105 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units | 0% | 923 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 32 | $0.00 |
| 74022 | 0% | 17 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 22 | $0.00 |
| 88304 | 0% | 13 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFILTON, STEVE (CFO, SENIOR VP)
| Provider | Location | Paid |
|---|---|---|
| District Hospital Partners L P | Washington, DC | $136.25M |
| Mcallen Hospitals L P | Edinburg, TX | $124.61M |
| Lancaster Hospital Corporation | Palmdale, CA | $108.63M |
| Universal Health Services of Rancho Springs INC | Murrieta, CA | $61.95M |
| Doctors Hospital of Laredo | Laredo, TX | $52.31M |
| Valley Hospital Medical Center | Las Vegas, NV | $47.03M |
| Northwest Texas Healthcare System INC | Amarillo, TX | $44.81M |
| Uhs of Bowling Green LLC | Bowling Green, KY | $41.21M |
| Uhs-Corona INC | Corona, CA | $35.18M |
| Spring Valley Medical Center | Las Vegas, NV | $33.58M |
| Aiken Regional Medical Centers LLC | Aiken, SC | $31.51M |
| Summerlin Hospital Medical Center L L C | Las Vegas, NV | $30.26M |
| Desert Springs Hospital | Las Vegas, NV | $22.29M |
| Fort Duncan Medical Center LP | Eagle Pass, TX | $15.80M |
| Psi Pride Institute INC | Eden Prairie, MN | $15.57M |
| Uhs of Fuller INC | S Attleboro, MA | $13.47M |
| Uhs of Texoma, INC | Denison, TX | $12.51M |
| Arbour INC | Boston, MA | $12.36M |
| Wellington Regional Medical Center LLC | Wellington, FL | $10.75M |
| Friends Behavioral Health System, LP | Philadelphia, PA | $9.55M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.